Gedeon Richter PLC Fair Value: 47.8% Upside (0QFP)

Gedeon Richter PLC Fair Value Analysis: Significant Upside Ahead

Gedeon Richter PLC (0QFP), a leading Hungarian pharmaceutical company, currently trades at GBP 50.4. Our comprehensive fair value assessment places its intrinsic worth at GBP 74.5, implying 47.8% upside potential and a Quality Score of 69/100. This positions the stock as undervalued based on our multi-model approach covering 21 valuation frameworks.

What Does Gedeon Richter PLC Do?

Gedeon Richter specialises in original drug research, women's healthcare, biosimilars and central nervous system treatments. The company maintains a strong presence across Europe and emerging markets, with a portfolio that blends innovative products and high-value generics. Recent performance highlights include double-digit growth in key segments like women's health and biosimilars.

Recent Performance and Market Context

In 2025, Gedeon Richter delivered pharma revenues of HUF 914 billion, up 8.2% year-on-year, with Clean EBIT rising 14% to beat guidance. Free cash flow remained robust at HUF 250 billion. Q1 2026 results showed continued momentum with constant-exchange-rate revenue growth of 5.9% and strong cash generation, prompting the company to reaffirm its full-year 2026 guidance for high-single-digit growth in both revenues and Clean EBIT.

Why Our Model Shows Gedeon Richter PLC Is Undervalued

Our fair value calculation for Gedeon Richter PLC incorporates earnings growth, cash flow durability, margin expansion from efficiency programmes and the company's strategic focus on high-margin areas. Despite solid fundamentals and positive analyst sentiment, the share price has not fully reflected these strengths, creating an attractive entry point at current levels.

Key valuation drivers include:

• Consistent revenue growth in core therapeutic areas
• Strong free cash flow supporting dividends and reinvestment
• Reiterated 2026 guidance signalling management confidence
• Attractive multiples relative to growth prospects

Main Risks to Consider

Like any pharmaceutical stock, Gedeon Richter PLC faces regulatory hurdles, potential patent expirations, R&D execution risks and currency volatility given its Hungarian base. Competition in the biosimilars space and broader economic conditions could also influence performance. Investors should monitor upcoming earnings for any shifts in guidance.

Balanced Verdict on Gedeon Richter PLC

With our fair value at GBP 74.5 and a meaningful upside to the current GBP 50.4 price, Gedeon Richter PLC appears undervalued. The combination of proven execution, growth visibility and a solid Quality Score makes it a stock worth monitoring closely. For the latest data and to run your own scenarios, try the free Fair Value Calculator to check Gedeon Richter PLC alongside thousands of other equities.

Discover more about valuation techniques on our fair value calculator homepage.

Frequently Asked Questions

Is Gedeon Richter PLC undervalued at current prices?

Yes, our fair value model indicates Gedeon Richter PLC (0QFP) is undervalued with a fair value of GBP 74.5 versus the current price of GBP 50.4, representing 47.8% upside potential and a Quality Score of 69/100.

What are the key drivers behind Gedeon Richter's valuation?

Strong revenue growth in women's health and biosimilars, robust free cash flow, high-single-digit 2026 guidance at constant exchange rates, and efficient operations support our fair value estimate for Gedeon Richter PLC.

What risks should investors consider with Gedeon Richter PLC?

Key risks for Gedeon Richter PLC include regulatory changes in pharma, currency fluctuations, R&D pipeline outcomes, competition in biosimilars, and broader market or geopolitical factors affecting the Hungarian company.

Sources

Context gathered via live web search while writing this article:

• https://www.gedeonrichter.com/en/investors/financial-calendar
• https://uk.finance.yahoo.com/quote/0QFP.IL/news/
• https://stockinvest.us/digest/gedeon-richter-tops-revenue-estimates-and-lifts-2026-outlook-amid-strong-biosimilars-and-womens-health-sales
• https://simplywall.st/stocks/us/pharmaceuticals-biotech/otc-geds.f/richter-gedeon-vegyeszeti-gyar-nyilvanosan-mukodo-rt/information
• https://simplywall.st/stocks/hu/pharmaceuticals-biotech/buse-richter/gedeon-richter-shares
• https://www.morningstar.com/stocks/xbud/richter/quote
• https://finbox.com/BUSE:RICHTER/
• https://www.marketscreener.com/news/gedeon-richter-plc-approves-dividend-for-the-financial-year-2025-ce7f5dd8d881f32c

Educational analysis only — not financial advice and not a buy or sell recommendation. Valuations are model-based and may be wrong; past performance does not indicate future results.